Clinical Trials Logo

Clinical Trial Summary

To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.


Clinical Trial Description

Primary Objectives: - Obtain prospective and retrospective data on lesion development, surgical history and systemic therapy use in patients with vHL disease - Assess genotype-phenotype correlation between VHL mutation type and patterns of lesion development - Assess genotype-phenotype correlation for response to belzutifan in an organ-specific manner Secondary Objectives: --Obtain quality of life data in patients with vHL disease ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05955014
Study type Observational
Source M.D. Anderson Cancer Center
Contact Eric Jonasch, MD
Phone (713) 563-7232
Email ejonasch@mdanderson.org
Status Recruiting
Phase
Start date August 24, 2023
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT00470977 - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Phase 1/Phase 2
Terminated NCT00001803 - Von Hippel-Lindau Disease Genetic Epidemiology Study
Enrolling by invitation NCT00102544 - Use of Tracking Devices to Locate Abnormalities During Invasive Procedures N/A
Terminated NCT01015300 - Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease Phase 0